Pharmaceutical

Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032

Atrial fibrillation drugs' patent expiration is largely responsible for the predicted decline in sales between 2022 and 2032

Jul 13, 2023 - 20:00
Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032
Atrial fibrillation drugs' patent expiration is largely responsible for the predicted decline in sales between 2022 and 2032
Read the original article

Tags:

Previous Article

Aridis’s AR-301 monoclonal antibody to receive FDA QIDP designation

Next Article

HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

More colonoscopy news and research

More colonoscopy news and research

Nov 29, 2023

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT+: This chemist’s last startup sold for $4 billion....

Feb 29, 2024

Breast cancer screening should begin at 40, not 50, federal health panel recommends

Breast cancer screening should begin at 40, not 50, fed...

May 9, 2023